JAK inhibitors as a promising therapy for immune-mediated photodermatoses

Abstract

Immune-mediated photodermatoses (IMPs) are skin diseases caused by altered immune responses triggered by sunlight, including polymorphous light eruption (PMLE), actinic prurigo (AP), solar urticaria (SU), chronic actinic dermatitis (CAD), and hydroa vacciniforme (HV). Managing IMPs is challenging because of the need for rigorous sun protection and the poor response to conventional therapies, particularly in moderate-to-severe patients. Researchers are exploring new targeted therapies for IMPs, including Janus kinase (JAK) inhibitors, a novel class of small molecules that block the JAK–STAT signaling pathway. Several case reports and series show promising results. This study reviews the evidence-based rationale for using JAK inhibitors in IMP treatment, assessing their efficacy and safety.